, Volume 27, Issue 3, pp 198–202 | Cite as

Azithromycin: Single 1.5g dose in the treatment of patients with atypical pneumonia syndrome—A randomized study

  • S. Schönwald
  • I. Kuzman
  • K. Orešković
  • V. Burek
  • V. Škerk
  • V. Car
  • D. Božinović
  • J. Čulig
  • S. Radošević


An open comparative study was undertaken in order to assess the efficacy and safety of a single dose of azithromycin in the treatment of community-acquired atypical pneumonia. A total of 100 adult patients with atypical penumonia syndrome were randomized to receive 1.5 g of azithromycin as a single dose, or 500 mg once daily for 3 days. The presence ofMycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci, Coxiella burnetii, andLegionella pneumophila infection was diagnosed by serological tests. Control clinical examinations were performed 72h, 10–12 days and 4 weeks after treatment initiation. Among 96 patients (48 in each group) who were evaluable for clinical efficacyM. pneumoniae infection was confirmed in 24,C. pneumoniae in nine,C. psittaci in five,C. burnetii in six, andL. pneumophila in five. Forty-seven patients (97.9%) in each group were cured. Side effects were observed in two patients in the single-dose group, and one patient in the 3-day group. In conclusion, a single 1.5 g dose of azithromycin may be an alternative to the standard 3-day azithromycin regimen in the treatment of outpatients with atypical pneumonia syndrome.


Azithromycin Roxithromycin Mycoplasma Pneumoniae Fleroxacin Atypical Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levison, M. E.: Pneumonia, including necrotizing pulmonary infections (lung abscess). In:Isselbacher, K. J., Braunwald, E., Wilson, J. D., Martin, J. B., Fauci, A. S., Kasper, D. L. (eds.) Harrison's principles of internal medicine. McGraw-Hill, New York 1994, pp. 1184–1191.Google Scholar
  2. 2.
    Donowitz, G. R., Mandell, G. L.: Acute pneumonia. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.), Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 619–637.Google Scholar
  3. 3.
    Cunha, B. A., Ortega, A. M.: Atypical pneumonia Extrapulmonary clues guide the way to diagnosis. Postgrad. Med. 99 (1996) 123–132.PubMedGoogle Scholar
  4. 4.
    Hoepelman, I. M., Schneider, M. M. E.: Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 5 (1995) 145–167.CrossRefPubMedGoogle Scholar
  5. 5.
    Renaudin, H., Bebear, C.: Comparativein vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum. Eur. J. Clin. Microbiol. Infect. Dis. 9 (1990) 838–841.PubMedCrossRefGoogle Scholar
  6. 6.
    Felmingham, D., Robbins, M. J., Sanghrajka, M., Leakey, A., Ridgway, G. L.: Thein vitro activity of some 14-, 15- and 16-membered macrolides againstStaphylococcus spp.,Legionella spp.,Mycoplasma spp. andUreaplasma urealyticum. Drugs Exp. Clin. Res. 17 (1991) 91–99.PubMedGoogle Scholar
  7. 7.
    Ishida, K., Kaku, M., Irifune, K., Mizukane, R., Takemura, H., Yoshida, R., Tanaka, H., Usui, T., Suyama, N., Tomono, K., Koga, H., Kohno, S., Izumikawa, K., Hara, K.:In vitro andin vivo activities of macrolides againstMycoplasma pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 790–798.PubMedGoogle Scholar
  8. 8.
    Niki, Y., Kimura, M., Miyashita, N., Soejima, R.:In vitro andin vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Antimicrob. Agents Chemother. 38 (1994) 2296–2299.PubMedGoogle Scholar
  9. 9.
    Hammerschlag, M. R.: Antimicrobial susceptibility and therapy of infections caused byChlamydia pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 1873–1878.PubMedGoogle Scholar
  10. 10.
    Welsh, L., Gaydos, C., Quinn, T. C.:In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains ofChlamydia pneumoniae. Antimicrob. Agents Chemother. 40 (1996) 212–214.PubMedGoogle Scholar
  11. 11.
    Barry, A. L., Jones, R. N., Thornsberry, C.:In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32 (1988) 752–754.PubMedGoogle Scholar
  12. 12.
    Johnson, D. M., Erwin, M. E., Barrett, M. S., Briggs Gooding, B., Jones, R. N.: Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested againstLegionella species. Eur. J. Clin. Microbiol. Infect. Dis. 11 (1992) 751–755.PubMedCrossRefGoogle Scholar
  13. 13.
    Nimmo, G. R., Bull, J. Z.: Comparative susceptibility ofLegionella pneumophila andLegionella longbacheae to 12 antimicrobial agents. J. Antimicrob. Chemother. 36 (1995) 219–223.PubMedCrossRefGoogle Scholar
  14. 14.
    Keysary, A., Itzhaki, A., Rubinstein, E., Oron, C., Keren, G.: Thein vitro anti-rickettsial activity of macrolides. J. Antimicrob. Chemother. 38 (1996) 727–731.PubMedCrossRefGoogle Scholar
  15. 15.
    Foulds, G., Shepard, R. M., Johnson, R. B.: The pharmacokinetics of azithromycin in human serum and tissues J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 73–82.PubMedGoogle Scholar
  16. 16.
    Morris, D. L., De Souza, A., Jones, J. A., Morgan, W. E.: High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 859–861.PubMedCrossRefGoogle Scholar
  17. 17.
    Baldwin, D. R., Wise, R., Andrews, J. M., Ashby, J. P., Honeybourne, D.: Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3 (1990) 886–890.PubMedGoogle Scholar
  18. 18.
    Schönwald, S., Gunjača, M., Kolačny-Babić, L., Car, V., Gošev, M.: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 123–126.PubMedGoogle Scholar
  19. 19.
    Schönwald, S., Škerk, V., Petričević, I., Car, V., Majerus-Mišić, Lj., Gunjača, M.: Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 877–880.PubMedCrossRefGoogle Scholar
  20. 20.
    Schönwald, S., Baršić, B., Klinar, I., Gunjača, M.: Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis. 26 (1994) 706–710.PubMedCrossRefGoogle Scholar
  21. 21.
    Kuzman, I., Schönwald, S., Čulig, J., Orešković, K.: Azithromycin, erythromycin and doxycycline in the treatment ofMycoplasma pneumoniae pneumonia: a retrospective study. In:Berkarda, B. (ed.). 10th Mediterranean Congress of Chemotherapy. Monduzzi Editore. Bologna 1996, pp. 211–214.Google Scholar
  22. 22.
    Kuzman, I., Orešković, K., Schönwald, S., Čulig, J.: Azithromycin in treatment of pneumonias caused byChlamydia spp.: a retrospective study. Int. J. Clin. Pharm. Res. 16 (1997) 103–107.Google Scholar
  23. 23.
    Kuzman, I., Soldo, I., Schönwald, S., Čulig, J.: Azithromycin for treatment of community-acquired pneumonia caused byLegionella pneumophila: a retrospective study. Scand. J. Infect. Dis. 27 (1995) 503–505.PubMedGoogle Scholar
  24. 24.
    Bohte, R., van't Wout, J.W., Lobatto, S., Blussé van Oud Alblas A., Boekhout, M., Nauta, E. H., Hermans, J., van den Broek, P. J.: Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14 (1995) 182–187.PubMedCrossRefGoogle Scholar
  25. 25.
    Sočan, M.: Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J. Chemother. 10 (1998) 64–68.PubMedGoogle Scholar
  26. 26.
    Kuzman, I.: Community-acquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy (doctoral thesis). Zagreb University, Zagreb 1994.Google Scholar
  27. 27.
    Tartakovskii, I. S., Sinopalnikov, A. J., Martinova, V. R., Gorina, L. G., Komissarov, A. L., Rakov, A. J., Prosorovskii, S. V.: Communityacquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy. In: Legionella infections and atypical pneumonias. Proceedings of the 11th meeting of the European Working Group on Legionella Infections. Oslo, Norway, 2–4 June 1996. The Norwegian Defence Microbiological Laboratory, Joint Medical Services, HQ Defense Command Norway, Oslo 1996, pp. 149–152.Google Scholar
  28. 28.
    The Nordic Atypical Pneumonia Study Group: Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. J. Antimicrob. Chemother. 39 (1997) 499–508.CrossRefGoogle Scholar
  29. 29.
    Lieberman, D., Ben-Yaakov, M., Lazarovich, Z., Porath, A., Schaeffer, F., Lieberman, D., Leinonen, M., Saikku, P., Horovitz, O., Boldur, I.: Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients Infection 24 (1996) 109–114.PubMedCrossRefGoogle Scholar
  30. 30.
    Baum S. G.: Mycoplasma pneumoniae and atypical pneumonia. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1704–1713.Google Scholar
  31. 31.
    Grayston, T. J.: Chlamydia pneumoniae (TWAR). In:Mandell, G. L., Bennett, J. E., Dolin R. (eds.). Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1696–1701.Google Scholar
  32. 32.
    Stout, J. E., Yu, V. L.: Legionellosis. N. Engl. J. Med. 337 (1997) 682–687.PubMedCrossRefGoogle Scholar
  33. 33.
    Marrie, T. J.:Coxiella burnetii (Q fever). In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1727–1735.Google Scholar
  34. 34.
    Fitzgeorge, R. B., Featherstone, A. S. R., Baskerville, A.: Efficacy of azithromycin in the treatment of guinea pigs infected with,Legionella pneumophila by aerosol. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 101–108.PubMedGoogle Scholar
  35. 35.
    Fitzgeorge, R. B., Lever, S., Baskerville, A.: A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne legionnaires' disease. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 171–176.PubMedGoogle Scholar
  36. 36.
    Malinverni, R., Kuo, C. C., Campbell, L. A., Lee, A., Grayston, J. T.: Effects of two antibiotic regimens on course and persistence of experimentalChlamydia pneumoniae TWAR pneumonitis. Antimicrob. Agents Chemother. 39 (1995) 45–49.PubMedGoogle Scholar
  37. 37.
    Cunha, B. A.: The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med. Clin. North Am. 79 (1995) 581–597.PubMedGoogle Scholar

Copyright information

© MMV Medien & Medizin VerlagsGmbH 1999

Authors and Affiliations

  • S. Schönwald
    • 1
  • I. Kuzman
    • 1
  • K. Orešković
    • 2
  • V. Burek
    • 1
  • V. Škerk
    • 1
  • V. Car
    • 1
  • D. Božinović
    • 1
  • J. Čulig
    • 2
  • S. Radošević
    • 2
  1. 1.University Hospital of Infectious Diseases “Dr. Fran Mihaljevic”ZagrebCroatia
  2. 2.Plivad.d. Pharmaceuticals Div.ZagrebCroatia

Personalised recommendations